Allscripts (MDRX) Misses Q1 EPS by 10c; Affirms Outlook
Allscripts (NASDAQ: MDRX) reported Q1 EPS of $0.13, $0.10 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $143 million, versus $133.7 million reported last year.
Allscripts is affirming its prior annual outlook and currently expects to achieve:
Veradigm revenue growth year-over-year between 6% to 7%
Veradigm adjusted EBITDA growth year-over-year between 10% to 15%
Free cash flow from continuing operations between $110 million to $120 million.
For earnings history and earnings-related data on Allscripts (MDRX) click here.